A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714713 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

830

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Impaired Cognition

Interventions

DRUG: EVP-6124

Sponsor

FORUM Pharmaceuticals Inc

Collaborators

[object Object]